Data from Therapeutic Effects of Deleting Cancer-Associated Fibroblasts in Cholangiocarcinoma
Joachim C. Mertens(GastroZentrum Hirslanden Zürich), Gregory J. Gores(Mayo Clinic in Arizona), Alphonse E. Sirica(Virginia Commonwealth University), Lewis R. Roberts(Mayo Clinic), Michael P. Gustafson(Mayo Clinic), Rory L. Smoot(Pancreas Centre (Canada)), John D. Christensen(NOAA National Ocean Service), Nathan W. Werneburg(Mayo Clinic), Christian D. Fingas(Essen University Hospital), Steven F. Bronk(Mayo Clinic), Allan B. Dietz(Mayo Clinic)
Cited by 0
Related Papers
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
|Hepatology|2018|4.7k
AASLD guidelines for the treatment of hepatocellular carcinoma
|Hepatology|2017|4.2k
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer
|Cell|2018|2.8k
Hepatocellular carcinoma
|Nature Reviews Disease Primers|2016|2.7k
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k